Practical Neurology

12/20/2025

Treatment with , a small molecule kinase, was associated with significant improvements in clinical and outcomes in people with with bodies.
https://ow.ly/Fqj650XMM8u
Alzheimer's Association American Academy of Neurology (AAN)

Treatment with neflamapimod (CervoMed, Boston, MA) —an investigational, orally administered small molecule kinase inhibitor—was associated with significan…

12/19/2025

In people with relapsing , GFAP levels correlated with clinical and MRI outcomes, according to a post hoc analysis of the SUNBEAM and RADIANCE clinical trials.
National Multiple Sclerosis Society The Consortium of Multiple Sclerosis Centers

Results of a post hoc analysis of phase 3 trials of Zeposia (ozanimod; Bristol Myers Squibb, New York, NY) showed that higher baseline plasma concentr

12/18/2025

The cover for our November issue was painted by Jennifer Zelinske, an artist who experiences . Painting brings Jen joy and allows her to raise awareness about . Her work can viewed on her Facebook (https://ow.ly/QtxI50XLwqB) and Instagram (https://ow.ly/k0J450XLwqy) pages.
American Epilepsy Society American Academy of Neurology (AAN) Epilepsy Foundation of America

12/17/2025

At , a distinguished group of clinicians, researchers, and public-health leaders were recognized with awards from American Epilepsy Society.
https://ow.ly/1hB550XK1Yv
American Academy of Neurology (AAN) Thomas Jefferson University

At the 2025 Annual Meeting, the American Epilepsy Society will honor a distinguished group of clinicians, researchers, and public-health leaders with its …

12/17/2025

Results from a study presented at suggest that (Xenon Pharmaceuticals), a Kv7 potassium channel opener, can support sustained seizure freedom in people with focal onset .
https://ow.ly/TnIY50XK1VM
American Epilepsy Society American Academy of Neurology (AAN)

Long-term data from the ongoing X-TOLE (NCT03796962) open-label extension (OLE) study suggest that azetukalner (XEN1101; Xenon Pharmaceuticals, Vancouver,…

12/17/2025

Treatment with ( ; SK Life Science, Inc.) showed potential efficacy as an adjunctive treatment for spasms in children with Infantile Epileptic Spasms Syndrome.
https://ow.ly/OZrB50XK1TA
American Epilepsy Society American Academy of Neurology (AAN) Child Neurology Society

Xcopri (cenobamate; SK Life Science, Paramus, NJ), an antiseizure therapy approved for refractory focal seizures in adults, has demonstrated potential eff…

12/16/2025

Individuals with who also have face significantly higher rates of treatment failure and shorter durations of initial treatment, according to data presented at . https://ow.ly/vrVa50XK1Ly
American Epilepsy Society American Psychiatric Association American Academy of Neurology (AAN)

Individuals diagnosed with epilepsy who also have depression face significantly higher rates of treatment failure and shorter durations of initial treatme…

12/15/2025

Adult increasingly encounter genetic disorders with childhood origins or late-onset phenotypes. Leslie Hayes, MD (Boston Children’s Hospital) reviews diagnostic guidance and management considerations across , CMT, myotonic , and .
https://ow.ly/TkMI50XK2MC
American Association of Neuromuscular & Electrodiagnostic Medicine - AANEM American Academy of Neurology (AAN) Cure SMA

Genetic pediatric neuromuscular disorders are becoming increasingly prevalent in the adult neurology clinic

12/13/2025

New clinical practice guidelines for the diagnosis and management of functional have been published in the Neurology Journal by the American Academy of Neurology (AAN) endorsed by the American Epilepsy Society.

The American Academy of Neurology (AAN) has published new clinical practice guidelines in Neurology, providing evidence-based recommendations for the diag…

12/12/2025

The U.S. Food and Drug Administration has approved ( ; Amgen) for the treatment of people with AChR+ or MuSK+ generalized .
https://ow.ly/rKma50XIJ5i
Myasthenia Gravis Foundation of America, Inc. American Association of Neuromuscular & Electrodiagnostic Medicine - AANEM American Academy of Neurology (AAN)

The Food and Drug Administration (FDA) has approved Uplizna (inebilizumab-cdon; Amgen, Thousand Oaks, CA) for the treatment of generalized myasthenia grav…

12/11/2025

Behavioral and psychiatric comorbidities are common in ; Dr. Waldron (David Geffen School of Medicine at UCLA) reviews evidence-based options, from SSRIs and antipsychotics, to medications and ASMs that support mood and behavior. https://ow.ly/FV0c50XHaZn
American Epilepsy Society UCLA Health Child Neurology Society American Psychiatric Association

Treatment of behavioral/psychiatric comorbidities requires consideration of underlying causes, symptom profile, antiseizure medications, and epilepsy type

12/10/2025

DEE-SWAS remains difficult to treat, with heterogeneous presentations, variable responses, and urgent need for standardized approaches to therapy and outcome measurement. In a new review article, Drs. Rao, Stowe, Kelley, Pavuluri, Liu, & Patel examine current challenges and paths forward.
https://ow.ly/ahfO50XGGgk
UCLA Health Boston Children’s Hospital Johns Hopkins Medicine Children's Nebraska CHOC Duke University School of Medicine American Epilepsy Society American Academy of Neurology (AAN)